PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications - PubMed (original) (raw)
Comparative Study
doi: 10.1177/0091270009344987. Epub 2010 Jan 23.
Affiliations
- PMID: 20097935
- DOI: 10.1177/0091270009344987
Comparative Study
PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications
Adel H Karara et al. J Clin Pharmacol. 2010 Apr.
Abstract
The FDA guidance on exploratory IND studies is intended to enable sponsors to move ahead more efficiently with the development of promising candidates. A survey of PhRMA member companies was conducted in 2007 to obtain a cross-sectional industry perspective on the current and future utility of exploratory IND studies. About 56% of survey responders (9 companies of 16 survey responders) conducted or were planning to conduct clinical studies under exploratory INDs. The majority of microdosing studies are performed to characterize human pharmacokinetics or to examine target organ pharmacokinetics using PET imaging techniques. On the other hand, the majority of pharmacological end point studies conducted under exploratory IND are performed to determine whether the compound modulated its pharmacological target or to evaluate the degree of saturation of a target receptor. The present survey suggests that although the merits of exploratory INDs are still being debated, the diversity in the applications cited, the potential for early clinical guidance in decision making and the increasing pressure on containing drug development costs, suggest that the exploratory IND/CTA will be a valuable option with evolving and possibly more specific applications for the future.
Similar articles
- Innovative early development regulatory approaches: expIND, expCTA, microdosing.
Robinson WT. Robinson WT. Clin Pharmacol Ther. 2008 Feb;83(2):358-60. doi: 10.1038/sj.clpt.6100461. Epub 2007 Dec 19. Clin Pharmacol Ther. 2008. PMID: 18091759 Review. - Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH. Takimoto CH. Cancer Chemother Pharmacol. 2009 Mar;63(4):703-9. doi: 10.1007/s00280-008-0789-4. Epub 2008 Jul 10. Cancer Chemother Pharmacol. 2009. PMID: 18615251 Review. - Leveraging exploratory investigational new drug studies to accelerate drug development.
Jacobson-Kram D, Mills G. Jacobson-Kram D, et al. Clin Cancer Res. 2008 Jun 15;14(12):3670-4. doi: 10.1158/1078-0432.CCR-07-4558. Clin Cancer Res. 2008. PMID: 18559581 - The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
Schwarz SW, Oyama R. Schwarz SW, et al. J Nucl Med. 2015 Apr;56(4):497-500. doi: 10.2967/jnumed.114.146472. Epub 2015 Mar 12. J Nucl Med. 2015. PMID: 25766895
Cited by
- In vitro platforms for evaluating liver toxicity.
Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, McCarty WJ, Bakan A, Bhushan A, Shun TY, Golberg I, DeBiasio R, Usta BO, Taylor DL, Yarmush ML. Bale SS, et al. Exp Biol Med (Maywood). 2014 Sep;239(9):1180-1191. doi: 10.1177/1535370214531872. Epub 2014 Apr 24. Exp Biol Med (Maywood). 2014. PMID: 24764241 Free PMC article. Review. - New era for drug discovery and development in renal disease.
Miyata T, Kikuchi K, Kiyomoto H, van Ypersele de Strihou C. Miyata T, et al. Nat Rev Nephrol. 2011 Jul 5;7(8):469-77. doi: 10.1038/nrneph.2011.84. Nat Rev Nephrol. 2011. PMID: 21727928 Review. - Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC, Langer O. Wagner CC, et al. Adv Drug Deliv Rev. 2011 Jun 19;63(7):539-46. doi: 10.1016/j.addr.2010.09.011. Epub 2010 Sep 29. Adv Drug Deliv Rev. 2011. PMID: 20887762 Free PMC article. Review. - Evaluation of agile designs in first-in-human (FIH) trials--a simulation study.
Perlstein I, Bolognese JA, Krishna R, Wagner JA. Perlstein I, et al. AAPS J. 2009 Dec;11(4):653-63. doi: 10.1208/s12248-009-9141-0. Epub 2009 Sep 16. AAPS J. 2009. PMID: 19763840 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical